Pricing Log in Create free account
Saturday 31 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

273.71 1.49 −0.54%
Market cap
$662.5B
P/E
31.7×
Fwd P/E
38.6×
Dividend yield
1.93%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Johnson & Johnson (JNJ) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 27, 2026 P1I2: 25 added · 29 removed · 35 modified
P2I1A: no comparison — the Item was not found
8-K Oct 13, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 4, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Jul 29, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jul 27, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 28, 2026 P1I2: 48 added · 13 removed · 34 modified
P2I1A: no comparison — the Item was not found
8-K Jul 15, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 23, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 29, 2026
8-K Apr 14, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 28, 2025 1: 2 added · 4 removed · 21 modified
1A: 5 added · 10 modified
7: 27 added · 31 removed · 57 modified
8-K Jan 21, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 28, 2025
8-K Oct 14, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 8, 2025 5.02 Departure or appointment of directors or officers
10-Q Jun 29, 2025
8-K Jul 16, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 30, 2025
8-K Apr 15, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 29, 2024
8-K Jan 22, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 29, 2024
8-K Oct 15, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 17, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Apr 16, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 23, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.